Exchange: NYSE·Updated 07:57 PM EDT

MRK News

News
all
press releases
BNTX, NVAX, MRNA Lead Vaccine Rally After Report Of An NIH Cancer-Vaccine Push
National Cancer Institute’s director, Dr. Anthony Letai, wants a national effort behind the vaccines, The New York Times reported on Friday.
Stocktwits
BNTX, NVAX, MRNA Lead Vaccine Rally After Report Of An NIH Cancer-Vaccine Push
National Cancer Institute’s director, Dr. Anthony Letai, wants a national effort behind the vaccines, The New York Times reported on Friday.
Stocktwits
More News
HALO Wins Court Order Blocking Merck's Keytruda SC in Europe
Halozyme wins a Dutch court order blocking Merck's Keytruda SC in eight European markets, strengthening its position in the patent dispute.
Zacks
Pfizer's Oncology Outlook: Key Drivers to Watch Ahead of Q3 Results
PFE's oncology growth in Q3 hinges on key drug sales, biosimilars and progress across a late-stage pipeline.
Zacks
INVA vs. MRK: Which Stock Is the Better Value Option?
INVA vs. MRK: Which Stock Is the Better Value Option?
Zacks
PFE, LLY, MRK Stocks In Focus: Cantor Raises Price Targets On Pharma Behemoths, But Flags Growth Concerns For Pfizer
The firm said Pfizer’s near-term performance largely depends on results from the Mevpro-1 trial of Mevrometostat, an experimental prostate cancer drug.
Stocktwits
Moderna's Nasdaq-100 Entry: What Does It Mean for the Stock?
MRNA's Nasdaq-100 entry follows a 566% stock surge and stronger cancer therapy prospects, potentially boosting demand from index-tracking funds.
Zacks
How Is Eli Lilly's Oncology Portfolio Poised Ahead of Q3 Earnings?
LLY's oncology portfolio is poised for growth as Jaypirca, Inluriyo and Retevmo may offset slower Verzenio sales and mature-drug declines.
Zacks
2026 Brings New Hope in the Fight Against Cancer as Breakthroughs Gather Momentum
NeOnc Technologies (NASDAQ:NTHI), Revolution Medicines (NASDAQ:RVMD), Moderna (NASDAQ:MRNA), Merck (NYSE:MRK), Johnson & Johnson (NYSE:JNJ), Genmab (NASDAQ:GMAB), and AbbVie (NYSE:ABBV) are among the companies contributing to a rapidly evolving cancer-treatment landscape in 2026, as researchers pursue new ways to extend survival, target tumors more precisely and give patients additional treatment options.
24-7 Market News
Merck (MRK) Beats Stock Market Upswing: What Investors Need to Know
Merck (MRK) reached $141.94 at the closing of the latest trading day, reflecting a +1.72% change compared to its last close.
Zacks
Merck Stock Down 7% in a Month: Is the Dip a Buying Opportunity?
Merck's 7% dip may offer a buying opportunity as Keytruda drives growth and new products and pipeline assets strengthen its post-2028 outlook.
Zacks

Advertisement|Remove ads.